The government’s 'Fit for the Future' 10-Year Health Plan outlines a strategic shift in NHS priorities, moving from a model of reactive treatment to one focused on proactive prevention. This shift aims to leverage advances in technology, diagnostics, and public health policy to transform the delivery of healthcare in England. The stated aims are to reduce long-term disease burdens, address health inequalities, and create a more financially sustainable healthcare system.
This analysis, the second in our series, examines the key components of this prevention strategy and assesses the implications for healthcare professionals and the life sciences industry.
The plan's prevention strategy is underpinned by a fundamental change from reactive to proactive care. The goal is to create a health service that can act based not only on a patient's current needs but also on their future health risks. This approach is built on the increasing capabilities of genomic science and predictive analytics to anticipate and mitigate the likelihood of disease.
A central pillar of the long-term strategy is the creation of a new genomics population health service, which aims to be accessible to all by the end of the decade. This initiative will build on existing NHS genomics infrastructure with several key ambitions:
Newborn screening: The plan proposes implementing universal newborn genomic testing, informed by insights from the ongoing Generation Study, to identify and treat rare genetic conditions earlier.
Adult risk prediction: A new large-scale study will be launched to sequence the genomes of 150,000 adults to assess how genomics can be used in routine preventive care for common diseases.
Pharmacogenomics: The plan is to integrate pre-emptive genomic testing into routine clinical practice to optimise medication effectiveness and prevent adverse drug reactions, which are estimated to cost the NHS up to £2.2 billion per year.
The strategy also relies on the earlier diagnosis and management of conditions that drive significant NHS activity.
Key policies include:
Targeted screening: The full national rollout of lung cancer screening for those with a history of smoking, which is expected to detect 9,000 cancers earlier each year.
New commercial models: The plan commits to expanding NHS access to new weight loss medications, such as GLP-1 receptor agonists. Crucially for the pharmaceutical industry, this will be tested through innovative "pay for impact on health outcomes" partnerships, where payment is linked to achieving results like fewer heart attacks or cancer diagnoses.
The plan identifies several large-scale public health programmes, described as "moonshots," to tackle major drivers of preventable ill health. These include:
A smoke-free generation: Using the ‘Tobacco and Vapes Bill’ to stop those turning 16 this year or younger from ever being legally sold tobacco.
Ending the obesity epidemic: This involves a range of policies, from restricting junk food advertising targeted at children to introducing mandatory healthy food sales reporting for all large companies in the food sector.
A core objective woven throughout the prevention agenda is to address the disparities in health outcomes across the country. The plan sets a clear, measurable target: to halve the gap in healthy life expectancy between the richest and poorest regions, while increasing it for everyone.
The shift to prevention is presented as a direct response to the UK's fiscal challenges. The plan references projections that, without intervention, government health spending will rise from around 8% of GDP today to 14.5% by 2073-74. By focusing on prevention, the goal is to "bend the cost curve" and reduce the number of people leaving the workforce due to ill health—a figure that has risen by half a million since 2020.
The successful implementation of this strategy faces several practical challenges:
Technology and skills uptake: Rolling out population-wide genomics requires substantial investment in training. The plan acknowledges this by proposing new roles like "genomics champions" and the need for skills in "genomic counselling" within community teams, highlighting a future need for specialised training and development.
Public engagement: A preventative model relies on individuals participating in screening and acting on personalised risk information. This will require effective public communication and a high level of trust.
Resource allocation: Directing funds towards preventative services, especially in areas with the greatest health needs, will require a shift in commissioning priorities.
The NHS's shift from sickness to prevention is a long-term, structural change. By building a framework around genomics, predictive diagnostics, and targeted public health policy, the plan sets a clear direction for the next decade. Its success will depend on sustained investment, effective policy execution, and robust collaboration between the NHS, industry, and the public.
This analysis is the second in our three-part series. In the final post, we will examine the third core shift: the move from hospital-centric services to a new model of community-based care.
Explore our latest thinking, event updates and industry insights to stay informed.
Learn how the NHS 10-Year Plan for England is decentralising care with new community health centres, expanded pharmacy roles, and virtual care models.
Discover how the NHS is going digital in 2025—from the UK Single Patient Record to AI-powered care, wearables and digital therapeutics via the NHS App.
CHASE’s 2024 gender pay gap report highlights progress and ongoing commitment to closing pay gaps and promoting equality in pharma, medtech and biotech sectors.
.svg)
